Atypical Antipsychotics To Add Warning About Metabolic Effects In Kids
Executive Summary
FDA likely will move metabolic information to the warning section in labeling for all atypical antipsychotics, according to Division of Psychiatry Products Director Thomas Laughren
You may also be interested in...
Pediatric Weight Gain From Atypical Antipsychotics Returns To FDA Advisory Cmte.
Panel urged label changes two years ago, but the products still do not include uniform information in their warning sections. FDA is asking its Pediatric Advisory Committee to review the pediatric safety of Bristol/Otsuka's Abilify, along with an AHRQ report on weight gain associated with the class of products.
Regulatory Updates, In Brief
Labopharm's once-daily trazodone gets regulatory nod: FDA cleared Oleptro, Labopharm's once-daily formulation of the antidepressant trazodone, for treatment of major depressive disorder in adults Feb. 3. Commercialization plans for the extended release tablets appear to rest on when the specialty pharma confirms a marketing partner for the therapy. Labopharm said it is actively exploring alternatives that range from out-licensing to a distribution agreement under which it would retain some degree of co-promotion rights, to a full co-promotion arrangement under which the company would share sales functions with a partner. Labopharm has completed market research with physicians and third-party payers, developed a positioning and marketing campaign and finalized manufacturing and packaging arrangements, so it would appear it is readying Oleptro to be a turn-key opportunity. Oleptro should be available later this year, with a launch to be determined by the final commercialization plan
Regulatory Updates, In Brief
Labopharm's once-daily trazodone gets regulatory nod: FDA cleared Oleptro, Labopharm's once-daily formulation of the antidepressant trazodone, for treatment of major depressive disorder in adults Feb. 3. Commercialization plans for the extended release tablets appear to rest on when the specialty pharma confirms a marketing partner for the therapy. Labopharm said it is actively exploring alternatives that range from out-licensing to a distribution agreement under which it would retain some degree of co-promotion rights, to a full co-promotion arrangement under which the company would share sales functions with a partner. Labopharm has completed market research with physicians and third-party payers, developed a positioning and marketing campaign and finalized manufacturing and packaging arrangements, so it would appear it is readying Oleptro to be a turn-key opportunity. Oleptro should be available later this year, with a launch to be determined by the final commercialization plan